DPQ
Based on 4 publication(s) in Google Scholar
DPQ is a selective PARP-1 inhibitor that blocks PARP-1-mediated DNA damage repair and NAD+/ATP consumption, thereby inhibiting excessive inflammatory responses. DPQ inhibits NF-κB pathway activation, reduces the expression of pro-inflammatory factors (such as TNF-α, IL-6) and oxidative stress. DPQ can be used in inflammation-related studies of acute lung injury, myocardial infarction, and neurodegenerative diseases.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.68%
- CAS No.: 129075-73-6
- Formule: C18H26N2O2
- Masse moléculaire:302.41
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Immunology/Inflammation Compound Library
HY-L007
-
NF-κB Signaling Compound Library
HY-L014
-
Anti-Aging Compound Library
HY-L034
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Pyroptosis Compound Library
HY-L059
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Antidepressant Compound Library
HY-L108
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) DPQ
More
Activité biologique
|
PARP-1 |
DPQ (10 μM; pretreatment 30 min, treatment 2-8 h) significantly inhibits the mRNA expression of TNF-α, IL-1β, IL-6, CXCL-1, MIP-2 and iNOS in mouse peritoneal macrophages stimulated by LPS (100 ng/mL) [2].
DPQ (10 μM; pretreatment 30 min, treatment 2-8 h) inhibits the degradation of IkB-α and phosphorylation of NF-κB p65 in macrophages induced by LPS (100 ng/mL)，blocking the inflammatory signaling pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Mixed murine cortical neurons
-
Concentration:10 μM
-
Incubation Time:10 min pretreatment + 20 min NMDA exposure
-
Result:Reduced NMDA-induced neuronal apoptosis by 84% at 6 h and 50% at 24 h, restored ATP levels from 4% to 72% of control, and suppressed PARP activation.
-
Cell Line:Murine peritoneal macrophages
-
Concentration:10 μM
-
Incubation Time:30 min pretreatment + 2-8 h LPS stimulation
-
Result:Significantly decreased LPS-induced mRNA expression of TNF-α (50% reduction), IL-1β (40%), IL-6 (45%), CXCL-1 (35%), MIP-2 (40%), and iNOS (50%).
-
Cell Line:Murine peritoneal macrophages
-
Concentration:10 μM
-
Incubation Time:30 min pretreatment + 15-60 min LPS stimulation
-
Result:Blocked LPS-induced IkB-α degradation (50% inhibition at 15 min) and NF-κB p65 phosphorylation (40% reduction at 30 min).
DPQ (10 mg/kg; intraperitoneal injection; single dose; 4 weeks) improves cardiac function and reduced apoptosis and oxidative stress in myocardial infarction model of Wistar rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS-Induced Acute Lung Injury Model in C57BL/6 mice (male, 8-10 weeks old)
-
Dosage:10 μg/kg (dissolved in 0.01% DMSO (PBS)
-
Administration:Intraperitoneal injection, 30 min after LPS chanllenge (7.5 mg/kg; ip; single dose)
-
Result:Reduced neutrophil infiltration (50% decrease), MPO activity (40% decrease), and pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in lungs.
Restored vascular permeability (Evans blue extravasation reduced by 35%), and inhibited apoptotic cell death (TUNEL-positive cells decreased by 45%).
Suppressed NF-κB activation with reduced IkB-α degradation and p65 phosphorylation.
-
Animal Model:Myocardial Infarction model in Wistar rats (male, 4 months old) via coronary artery ligation[3]
-
Dosage:10 mg/kg (dissolved in DMSO)
-
Administration:Intraperitoneal injection, single dose immediately after MI induction
-
Result:Improved cardiac function (FS increased by 25%, EDD/ESD reduced by 15%), decreased apoptotic cardiomyocytes (TUNEL-positive cells reduced by 40%), and suppressed cleaved caspase-3 and PARP1 expression. Oxidative stress markers (O2-, nitrotyrosine) were reduced by 30-40% in infarcted myocardium.
Chemical Information
-
CAS No. 129075-73-6
-
Appearance Solid
-
Masse moléculaire 302.41
-
Formule C18H26N2O2
-
Color White to off-white
-
SMILES
O=C1C2=C(CCN1)C(OCCCCN3CCCCC3)=CC=C2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Sci Immunol
Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA. [Abstract]2024 Jun 14;9(96):eadj5465. PMID: 38875319 -
Adv Sci (Weinh)
Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation. [Abstract]2026 May;13(25):e15367. PMID: 41722054 -
J Adv Res
Targeting myofibroblast copper vulnerability reverses pulmonary fibrosis via METTL3-directed STAT6 m6A driving cuproptosis. [Abstract]2026 May 21:S2090-1232(26)00436-4. PMID: 42173361 -
Stem Cell Res Ther
MSC-derived exosomes attenuate cell death through suppressing AIF nucleus translocation and enhance cutaneous wound healing. [Abstract]2020 May 11;11(1):174. PMID: 32393338
Solvant et solubilité
DMSO : 100 mg/mL (330.68 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Meli E, et al. Differential role of poly (ADP-ribose) polymerase-1in apoptotic and necrotic neuronal death induced by mild or intense NMDA exposure in vitro. Mol Cell Neurosci. 2004;25 (1) :172-180. [Content Brief]
[2]. Wang G, et al. PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-κB-mediated inflammatory response. PLoS One. 2013 Nov 21;8 (11) :e79757. [Content Brief]
[3]. Wang J, et al. Inhibition of poly (ADP-ribose) polymerase and inducible nitric oxide synthase protects against ischemic myocardial damage by reduction of apoptosis. Mol Med Rep. 2015 Mar;11 (3) :1768-76. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3068 mL | 16.5338 mL | 33.0677 mL | 82.6692 mL |
| 5 mM | 0.6614 mL | 3.3068 mL | 6.6135 mL | 16.5338 mL | |
| 10 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL | 8.2669 mL | |
| 15 mM | 0.2205 mL | 1.1023 mL | 2.2045 mL | 5.5113 mL | |
| 20 mM | 0.1653 mL | 0.8267 mL | 1.6534 mL | 4.1335 mL | |
| 25 mM | 0.1323 mL | 0.6614 mL | 1.3227 mL | 3.3068 mL | |
| 30 mM | 0.1102 mL | 0.5511 mL | 1.1023 mL | 2.7556 mL | |
| 40 mM | 0.0827 mL | 0.4133 mL | 0.8267 mL | 2.0667 mL | |
| 50 mM | 0.0661 mL | 0.3307 mL | 0.6614 mL | 1.6534 mL | |
| 60 mM | 0.0551 mL | 0.2756 mL | 0.5511 mL | 1.3778 mL | |
| 80 mM | 0.0413 mL | 0.2067 mL | 0.4133 mL | 1.0334 mL | |
| 100 mM | 0.0331 mL | 0.1653 mL | 0.3307 mL | 0.8267 mL |
DPQ Related Classifications
HY-114869 Related Classifications
Powered by Bioz